Acrivon Therapeutics Inc
NASDAQ:ACRV
Acrivon Therapeutics Inc
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2022-11-15. The firm's lead clinical candidate ACR-368, is a selective small molecule inhibitor targeting CHK1/2. CHK1/2 are regulators of the cell cycle and of DNA Damage Response (DDR). The company also has two preclinical drug programs designed to take advantage of its AP3 platform and the ability to predict tumor sensitivity based on custom OncoSignature tests. Its AP3 platform is based on its proprietary approach developed to enable treatment of the patients who are most likely to respond to any particular drug candidate based on dependency in the tumor on the upregulated specific biochemical pathways that each drug modulates. The firm's OncoSignature tests are automated, quantitative proteomic tissue imaging tests applied to pre-treatment tumor biopsies as a companion diagnostic (CDx), to select and treat the patients predicted to benefit from the drug candidate.
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2022-11-15. The firm's lead clinical candidate ACR-368, is a selective small molecule inhibitor targeting CHK1/2. CHK1/2 are regulators of the cell cycle and of DNA Damage Response (DDR). The company also has two preclinical drug programs designed to take advantage of its AP3 platform and the ability to predict tumor sensitivity based on custom OncoSignature tests. Its AP3 platform is based on its proprietary approach developed to enable treatment of the patients who are most likely to respond to any particular drug candidate based on dependency in the tumor on the upregulated specific biochemical pathways that each drug modulates. The firm's OncoSignature tests are automated, quantitative proteomic tissue imaging tests applied to pre-treatment tumor biopsies as a companion diagnostic (CDx), to select and treat the patients predicted to benefit from the drug candidate.
